Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus ZUPLENZ.
COMPAZINE vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antiemetic